Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cmi.2020.12.032 http://scihub22266oqcxt.onion/10.1016/j.cmi.2020.12.032 33421580!7787506!33421580     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Microbiol+Infect 2021 ; 27 (3): 372-377 Nephropedia Template TP {{tp|p=33421580|t=2021. Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure |pdf=|usr=}}{{33421580}} gab.com Text Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure JO: Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=33421580 #FOAvip BACKGROUND: A vaccine trial with a conventional challenge design can be very fast once it starts, but it requires a long prior process, in part to grow and standardize challenge virus in the laboratory. This detracts somewhat from its overall promise for accelerated efficacy testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates, and from the ability of developing countries and small companies to conduct it. AIMS: We set out to identify a challenge design that avoids this part of the long prior process. SOURCES: Literature in trial design (including a proof of concept flu challenge trial by B. Killingley et al.), vaccinology, medical ethics, and various aspects of COVID response. CONTENT: A challenge design with deliberate natural viral exposure avoids the need to grow culture. This new design is described and compared both to a conventional challenge design and to a conventional phase III field trial. In comparison, the proposed design has ethical, scientific, and feasibility strengths. IMPLICATIONS: The proposed new design should be considered for future vaccine trials. Twit Text FOAVip Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure ????Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=33421580 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33421580 #FOAvip English Wikipedia <ref>{{Cite pmid|33421580}}</ref> Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral exposure #MMPMID33421580 Eyal N; Lipsitch M Clin Microbiol Infect 2021[Mar]; 27 (3): 372-377 PMID33421580show ga BACKGROUND: A vaccine trial with a conventional challenge design can be very fast once it starts, but it requires a long prior process, in part to grow and standardize challenge virus in the laboratory. This detracts somewhat from its overall promise for accelerated efficacy testing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine candidates, and from the ability of developing countries and small companies to conduct it. AIMS: We set out to identify a challenge design that avoids this part of the long prior process. SOURCES: Literature in trial design (including a proof of concept flu challenge trial by B. Killingley et al.), vaccinology, medical ethics, and various aspects of COVID response. CONTENT: A challenge design with deliberate natural viral exposure avoids the need to grow culture. This new design is described and compared both to a conventional challenge design and to a conventional phase III field trial. In comparison, the proposed design has ethical, scientific, and feasibility strengths. IMPLICATIONS: The proposed new design should be considered for future vaccine trials. |*Clinical Trials as Topic/ethics[MESH] |COVID-19 Vaccines/*administration & dosage/adverse effects/immunology[MESH] |COVID-19/immunology/*prevention & control/transmission[MESH] |Humans[MESH] |Research Design[MESH] |SARS-CoV-2/*immunology/isolation & purification[MESH] |Safety[MESH]Testing SARS-CoV-2 vaccine efficacy through deliberate natural viral e(epmc).pdf DeepDyve Pubget Overpricing